Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jun;74(6):1472-1482.
doi: 10.1016/j.jhep.2021.03.004. Epub 2021 Mar 12.

Treatment failure with DAA therapy: Importance of resistance

Christoph Sarrazin  1
Affiliations
Review

Treatment failure with DAA therapy: Importance of resistance

Christoph Sarrazin. J Hepatol. 2021 Jun.

Abstract

Viral resistance is a major reason for virological failure in patients being treated with direct-acting antivirals (DAAs) for chronic HCV infection. However, the importance of viral resistance mainly depends on the DAA regimen and HCV genotype. For first-line therapy with glecaprevir/pibrentasvir (G/P) or velpatasvir/sofosbuvir (VEL/SOF) no general baseline resistance analysis is required because of the high antiviral activity and high barrier to resistance. If available, resistance testing may help to optimise therapy in certain subgroups of patients with HCV genotype 3 and other rare HCV geno/subtypes. Voxilaprevir/velpatasvir/sofosbuvir (VOX/VEL/SOF) is the first choice for the second-line treatment of patients following a previous DAA failure, with rates of viral eradication above 90% irrespective of the presence of resistance-associated substitutions (RASs). However, in resource-limited settings, only first-generation DAAs may be available for second-line therapy. Here, RASs selected during initial antiviral therapy should be considered if testing is available and rescue treatment should include a switch to a regimen with a new DAA class to optimise treatment response. Patients with HCV genotype 3 are overrepresented in the group who experience DAA treatment failure. Limited data are available for third-line therapies, but promising results have been achieved with G/P plus SOF or VOX/VEL/SOF with or without ribavirin for 12 to 24 weeks; these regimens should be administered irrespective of a patient's RAS profile.

Keywords: Hepatitis C virus; antiviral therapy; direct-acting antiviral agents; rescue treatment; resistance-associated substitutions (RASs); resistance-associated variants (RAVs).

PubMed Disclaimer

Conflict of interest statement

Conflict of interest Advisory Committees: Abbvie, Gilead, Merck/MSD,. Grant/Research Support: Abbvie, Gilead, MSD. Speaking and Teaching: Abbvie, Gilead, Merck/MSD. Please refer to the accompanying ICMJE disclosure forms for further details.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

Publication types

MeSH terms

LinkOut - more resources